Key result
The optimal duration of dual anti-platelet therapy remains debated, with some trials showing non-inferiority of early cessation while larger trials demonstrate benefit of prolonged therapy.
Why the study?
What is the optimal duration of dual anti-platelet therapy in patients with coronary heart disease?
What is the optimal duration of dual anti-platelet therapy in patients with coronary heart disease?
The optimal duration of dual anti-platelet therapy remains debated, balancing the non-inferiority of early cessation in some trials against the benefits of prolonged therapy seen in the DAPT and PEGASUS-TIMI 54 trials.
Answers are grounded in this paper and cite their sources.
DAPT duration requires individualized ischemic-bleeding risk assessment; leaves open need for targeted trials in high-risk subgroups.
Dual anti-platelet therapy is prescribed in the setting of coronary heart disease for the prevention of stent thrombosis and acute thrombotic events. The optimal duration of dual anti-platelet therapy is still under debate as numerous trials have shown non-inferiority of a strategy of early cessation of one of the agents as compared to the standard practice whereas two larger trials have demonstrated benefit of prolonging dual anti-platelet therapy.
No takes yet. Share an insight, caveat, or question.
Pirlet et al. (2017) conducted a review in Coronary heart disease. Dual anti-platelet therapy duration vs. Standard practice was evaluated. The optimal duration of dual anti-platelet therapy remains debated, with some trials showing non-inferiority of early cessation while larger trials demonstrate benefit of prolonged therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: